Ascendis Pharma A (ASND) Other Non-Current Liabilities (2019 - 2026)

Ascendis Pharma A has reported Other Non-Current Liabilities for 8 years, with the latest figure at $67.1 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 67.6% year-over-year to $67.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.1 million (up 67.6% YoY) and the FY2025 annual result came in at $67.8 million, down 6.7% from the prior year.
• Other Non-Current Liabilities retreated to $67.1 million in Q1 2026 per ASND's latest filing, from $67.8 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $72.6 million in Q4 2024 and troughed at $14.1 million in Q1 2022.
• A 5-year average of $39.2 million and a median of $36.6 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities decreased 6.7% in 2025, then jumped 67.6% in 2026.
• Over 5 years, Other Non-Current Liabilities stood at $32.6 million in 2022, then soared by 35.75% to $44.3 million in 2023, then soared by 63.91% to $72.6 million in 2024, then declined by 6.7% to $67.8 million in 2025, then retreated by 0.96% to $67.1 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $67.1 million, $67.8 million, and $56.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.